<DOC>
	<DOCNO>NCT00701766</DOCNO>
	<brief_summary>The present trial perform determine MTD evaluate efficacy BI 2536 treatment elderly patient relapse refractory AML . Different schedule compare identify well dose schedule development programme BI 2536 . Dose escalation start maximum tolerate dose previously determine patient advance solid cancer perform determine maximum tolerate dose AML patient .</brief_summary>
	<brief_title>BI 2536 Infusional Treatment Patients Over 60 Years Age With Refractory Relapsed Acute Myeloid Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Male female patient older 60 year age Patient confirm AML ( except APL ) accord WHO definition relapse refractory prior chemotherapy Leukocyte count &lt; = 25,000 /mcl ( 25 x 10e9/Liter ) Patient eligible intensive treatment option Life expectancy &gt; = 2 month Eastern cooperative oncology group performance score 2 less Signed write informed consent consistent international conference harmonisation good clinical practice ( ICHGCP ) local legislation Patient acute promyelocytic leukaemia ( APL , AML FrenchAmericanBritish ( FAB ) classification subtype M3 ) Hypersensitivity trial drug excipients Secondary malignancy require therapy Known central nervous system involvement Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great 2.5 time upper limit normal , AST ALT great 5 time upper limit normal case know liver involvement Bilirubin great 1.5 mg/dl ( &gt; 26 mcmol/l , SI unit equivalent ) Serum creatinine great 2.0 mg/dl Concomitant intercurrent illness , would compromise evaluation efficacy safety trial drug , e.g . active severe infection , unstable angina pectoris cardiac arrhythmia Psychiatric illness social situation would limit compliance trial requirement Concomitant therapy , consider relevant evaluation efficacy safety trial drug Chemotherapy ( except hydroxyurea ) immunotherapy treatment investigational drug within past four week prior treatment trial drug Persistence toxicity prior antileukaemia therapy deem clinically relevant Patients sexually active unwilling use medically acceptable method contraception trial ( hormonal contraception , intrauterine device , condom spermicide , etc . ) Patient unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>